PEEP after EPVent-2 & ART: Now What?! CCCF PE… · ES = 28 cmw P AW P AW = 17 cmw Flow P ES P L...

of 50 /50
PEEP after EPVent-2 & ART: Now What?! Jeremy R. Beitler, MD, MPH Center for Acute Respiratory Failure Columbia University

Embed Size (px)

Transcript of PEEP after EPVent-2 & ART: Now What?! CCCF PE… · ES = 28 cmw P AW P AW = 17 cmw Flow P ES P L...

  • PEEP after EPVent-2 & ART: Now What?!

    Jeremy R. Beitler, MD, MPHCenter for Acute Respiratory FailureColumbia University

  • • Speaking fees from Hamilton Medical

    • Research Funding:• NIH

    • ATS Foundation

    Disclosures

  • High vs. Low PEEP in ARDS

    LOVS Trial. JAMA 2008ARDSNet ALVEOLI Trial. NEJM 2004

  • Respiratory Mechanics-based PEEP

    Express Trial. JAMA 2008 ART Trial. JAMA 2017

  • PL = Pairway – Ppleural

    Lung Mechanics-based PEEP

    Beitler et al. Clin Chest Med. 2016;37:633-646

    Could adjusting PEEP to maintain Pairway ≥ Ppleural prevent atelectrauma?

  • p = 0.13

    Difference in 28d mortality after adjusting for APACHE-II:RR 0.46 (95%CI 0.19-1.0); p = 0.049

    EPVent Trial

    PES-guided PEEP vs. empiric low PEEP

  • EPVent-2 Trial

    PES-guided PEEP vs. empiric high PEEP

  • What Happened?

  • If PL < 0 signifies atelectrauma, negligible difference over first few days in EPVent2

    PL Separation in EPVent1 vs. EPVent2

    EPVent2EPVent1

  • FiO2

    Control Arm 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

    EPVent PEEP 5 5-8 8-10 10 10-14 14 14-18 20-24

    EPVent2 PEEP 5-10 10-18 18-20 20 20 20-22 22 22-24

    EPVent2 Not a Validation Study of EPVent1

    EPVent2 asked a different research question:PES-guided PEEP vs. empirical high PEEP

  • FiO2Control Arm 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

    EPVent2 PEEP 5-10 10-18 18-20 20 20 20-22 22 22-24

    EPVent2 “Control” Arm Nothing Like Usual Care

    LUNG-SAFEEPVent2 Control Arm

  • PEEP & ARDS Severity

    Briel et al. JAMA. 2010;303:865-873

    PaO2:FiO2 ≤ 200 mmHg PaO2:FiO2 201-300 mmHg

  • Possible InterpretationHigh PEEP (without aggressive decremental PEEP trial) is superior to low PEEP in moderate-severe ARDS

  • Following are preliminary results

  • Heterogeneity of Treatment Effect

    1.0

    0.8

    0.6

    0.4

    0.2

    0

    6050403020100

    1.0

    0.8

    0.6

    0.4

    0.2

    0

    6050403020100

    PES-guided PEEP

    Empirical PEEP

    PES-guided PEEP

    Empirical PEEP

    P = 0.03 P = 0.08

    Surv

    iva

    l Pro

    ba

    bili

    ty

    Time (days) Time (days)

    Lower APACHE Higher APACHE

    Test for interaction term: p < 0.01

  • Attributable Risk of Death in ARDS

    Illness Severity

    Pro

    bab

    ility

    of

    Dea

    th

    EPVent2 enrolled low PaO2:FiO2 (≤ 200)

    • HTE analysis: benefit with lower APACHE

    ARDS attributable risk

    Non-ARDS attributable risk

    0.2

    0.4

    0.6

    0.8

    1.0

    • Sepsis• Baseline morbidity

    Examples:

  • Attributable Risk of Death in ARDS

    Illness Severity

    Pro

    bab

    ility

    of

    Dea

    th

    EPVent2 enrolled low PaO2:FiO2 (≤ 200)

    • HTE analysis: benefit with lower APACHE

    ARDS attributable risk

    Non-ARDS attributable risk

    0.2

    0.4

    0.6

    0.8

    1.0

  • Attributable Risk of Death in ARDS

    Illness Severity

    Pro

    bab

    ility

    of

    Dea

    th

    EPVent2 enrolled low PaO2:FiO2 (≤ 200)

    • HTE analysis: benefit with lower APACHE

    ARDS attributable risk

    Non-ARDS attributable risk

    0.2

    0.4

    0.6

    0.8

    1.0

  • Possible InterpretationPES-guided PEEP improves survival when risk of death is mostly due to ARDS

  • HTE Analysis in ART

  • ∆PAW and PL may yield Different PEEP values

    Change in Airway Driving Pressure

    Ch

    ange

    in E

    nd

    -exp

    irat

    ory

    PL

    -15 -10 0 +20

    -15

    -10

    -5

    0

    +5

    +20

    +25

    +15

    +10

    +25+5 +10 +15-5

    ß = -0.13 (95% CI -0.31 to 0.05)P = 0.16R2 = 0.01

  • More work to be done

  • Back to Physiology

  • -10

    0

    10

    20

    30

    P=0.56

    PL values have Intrinsic MeaningP

    L(c

    m H

    2O

    )

    PL at Total Lung Capacity in Health =20-25 cm H2O

    Physiologic FRC

    Normal end-insp. stress

  • -10

    0

    10

    20

    30

    P=0.56

    PEEP Competing EffectsP

    L(c

    m H

    2O

    )

    6 ml/kg∆P 12

    Atelectrauma

    Overdistension

    PL at Total Lung Capacity in Health =20-25 cm H2O

    6 ml/kg∆P 12

    6 ml/kg∆P 18 6 ml/kg

    ∆P 10

    Prevent atelectrauma(PL end-exp)

    Exacerbate overdistension(PL end-insp)

    Physiologic FRC

    Normal end-insp. stress

  • -10

    0

    10

    20

    30

    P=0.56

    PEEP Competing EffectsP

    L(c

    m H

    2O

    )Prevent atelectrauma

    (PL end-exp)

    Exacerbate overdistension(PL end-insp)

    Atelectrauma

    Overdistension

    6 ml/kg∆P 18 4 ml/kg

    ∆P 126 ml/kg∆P 18 6 ml/kg

    ∆P 16

    PL at Total Lung Capacity in Health =20-25 cm H2O

    Physiologic FRC

    Normal end-insp. stress

  • Ideal PEEP ≠ Higher PEEP

    27

    Ideal PEEP ≠ Lower PEEP

  • Ideal PEEP titration:Minimum Stress ApproachMust account for competing effects of mitigating atelectrauma and exacerbating overdistension with higher PEEP

  • Thank you

    Jeremy R. Beitler, MD, MPH

    [email protected]

  • Additional Slides for Q&A

  • Separation in PEEP & PL in EPVent2

  • • Huge range in end-inspiratory PLfor a given…

    • Plateau pressure

    PL versus Plateau Pressure

    Beitler et al. Crit Care Med. 2016;44:91-99.

  • PL versus Tidal Volume

    Beitler et al. Crit Care Med. 2016;44:91-99.

    • Huge range in end-inspiratory PLfor a given…

    • Plateau pressure

    • Tidal volume

  • PL versus Driving Pressure

    Beitler et al. Crit Care Med. 2016;44:91-99.

    • Huge range in end-inspiratory PLfor a given…

    • Plateau pressure

    • Tidal volume

    • Driving pressure

  • Model Marginal R2 Variable of Interest P-value

    Log(sRAGE) = Expiratory-PL + Day 14.2% Expiratory PL 0.04

    Log(sRAGE) = Inspiratory-PL + Day 15.5% Inspiratory PL < 0.01

    Log(sRAGE) = Inspiratory-PL +Expiratory-PL + Day

    15.6% Inspiratory PLExpiratory PL

    < 0.010.50

    Log(sRAGE) = dPL + Day 14.4% dPL 0.02

    PL & Alveolar Epithelial Injury

    Beitler, Talmor, for the EPVent2 Investigators. Unpublished data.

    Log(sRAGE) = PEEP + Day 13.2% PEEP 0.41

    Log(sRAGE) = Pplat + Day 13.4% Pplat 0.13

    Log(sRAGE) = dPairway + Day 13.6% dPairway 0.06

  • • PEEP effect on atelectrauma trivial in non-ZEEP era• No trial has proven definitively one strategy is superior to another

    • High PEEP better than low PEEP in moderate-severe ARDS• PES provides added safety assurance

    • PES-guided PEEP improves survival when ARDS-attributable risk of death is high

    Possible Interpretations

  • PL and Airway Opening Pressure

    Pairway

    Ppleural

    Volume

    Flow

    Original data, unpublished. Courtesy of D Talmor.

  • Setting PEEP to PL

    PES = 28 cmw

    PAW = 17 cmwPAW

    Flow

    PES

    PL

    Flow = 0 L/min

    PL = -11 cmw

    PES = 31 cmw

    PAW = 31 cmw

    Flow = 0 L/min

    PL = 0 cmw

    Baseline On PES-guided PEEP Protocol

  • End-Inspiratory Values

    PAW

    Flow

    PES

    PL

    Baseline On PES-guided PEEP Protocol

    PES = 31 cmw

    PAW = 31 cmw

    Flow = 0 L/min

    PL = 0 cmw

    PES = 38 cmw

    PAW = 46 cmw

    Flow = 0 L/min

    PL = 8 cmw

  • PL and Airway Opening Pressure

    PAW

    PES

    Volume

    Original data, unpublished. Courtesy of D Talmor.Slide courtesy of D. Talmor

  • Atelectrauma: Role for PEEP?

    Beitler et al. Clin Chest Med. 2016;37:633-646.

    Cressoni et al. AJRCCM. 2014;189:149-158.

    Bilek et al. JAP. 2003;94:770-783.

  • • PEEP effect on atelectrauma trivial in non-ZEEP era• No trial has proven definitively one strategy is superior to another

    Possible Interpretations

    PEEP

    Inju

    ry d

    ue

    to

    Ate

    lect

    rau

    ma

    0 5 10 15 20 25

    Inju

    ry d

    ue

    to

    Ove

    rdis

    ten

    sio

    n

  • Lower APACHE ≤ 27(n = 99)

    Higher APACHE > 27(n = 101)

    P-value

    Age 57 (42 to 67) 58 (47 to 67) 0.36

    Weight, kg 85.4 (72.0 to 110.3) 77.8 (69.0 to 96.5) 0.02

    Body mass index, kg/m2 31.1 (26.4 to 39.7) 28.3 (24.8 to 33.4) 0.01

    APACHE-II 21 ± 4 33 ± 4 < 0.01

    Vasopressors at baseline, no. (%) 45 (45.5%) 69 (68.3%) < 0.01

    PaO2:FiO2 95 (75 to 132) 86 (69 to 119) 0.20

    Airway driving pressure, cmH2O 13 (10 to 15) 13 (10 to 14) 0.80

    PES at end-expiration, cmH2O 16 (12 to 19) 16 (13 to 18) 0.34

    PL at end-expiration, cmH2O -1 (-4 to 2) -1 (-3 to 1) 0.81

    Randomization to PES-guided PEEP 51 (51.5%) 51 (50.5%) 0.89

    Heterogeneity of Treatment Effect

  • Differential Response to Treatment by Baseline Illness Severity in EPVent2

    Lower APACHE Higher APACHE P for interactionPES-guided Empirical PES-guided Empirical

    Mortality at day 28 8 (15.7) 13 (27.1) 25 (49.0) 17 (34.0) 0.04

    Mortality at day 60 10 (20.0) 19 (39.6) 28 (54.9) 18 (36.0) < 0.01

    Mortality at 1 year 14 (28.0) 22 (45.8) 30 (60.0) 22 (45.8) 0.02

    Ventilator-free days* 21 (6 to 24) 17.5 (0 to 24) 0 (0 to 21) 17.5 (0 to 22) < 0.01

    Shock-free days* 20 (11 to 23) 18 (0 to 22) 3 (0 to 18) 16 (0 to 20) < 0.01

    Acute kidney injury requiring renal replacement therapy*

    8 (15.7) 9 (18.8) 13 (25.5) 23 (46.0) 0.34

    Data presented as no. (%) or median (IQR).

    * Through day 28

  • Higher vs. Lower PEEP in Other Trials

    47Briel et al. JAMA. 2010;303:865-873

    PaO2:FiO2 ≤ 200 mmHg PaO2:FiO2 201-300 mmHg

    Pro

    bab

    ility

    of

    Surv

    ival

  • Ideal PEEP titrationMust account for competing effects of mitigating atelectrauma and exacerbating overdistension with higher PEEP

  • PEEP research:

    where good

    ideas go to

    die.

    Which PEEP strategy did

    these fools attempt to study

    this time?

  • Bring out your dead!

    I’m not dead yet!